共 263 条
- [1] Lee EC(2006)Targeting aurora kinases for the treatment of prostate cancer Cancer Res 66 4996-5002
- [2] Frolov A(2013)Gene expression of aurora kinases in prostate cancer and nodular hyperplasia tissues Med Princ Pract 22 138-143
- [3] Li R(2017)The expression of AURKA is androgen regulated in castration-resistant prostate cancer Sci Rep 7 17978-495
- [4] Ayala G(2011)Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets Cancer Discov 1 487-51
- [5] Greenberg NM(2018)A phase II trial of the aurora kinase an inhibitor alisertib for patients with castrationresistant and neuroendocrine prostate cancer: efficacy and biomarkers Clin Cancer Res 25 43-2533
- [6] Nna E(2016)Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors Cancer 122 2524-1375
- [7] Madukwe J(2016)Phase I study of the aurora a kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: a NANT (new approaches to neuroblastoma therapy) trial J Clin Oncol 34 1368-317
- [8] Egbujo E(2020)Phase 1 study of the aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies Leuk Lymphoma 61 309-2722
- [9] Obiorah C(2011)PHLDA1 is a crucial negative regulator and effector of aurora A kinase in breast cancer J Cell Sci 124 2711-1216
- [10] Okolie C(2012)LIMK2 is a crucial regulator and effector of aurora-A-kinase-mediated malignancy J Cell Sci 125 1204-1093